Background: Chemotherapy-induced nausea and vomiting (CINV) continue to be a distressing problem still reported by cancer patients, with negative consequences on quality of life (QoL). Aims: To prospectively explore the association of psychosocial variables, including emotional distress, maladaptive coping styles and the doctor-patient relationship, with CINV and QoL among cancer outpatients. Methods: A prospective study was conducted on 302 consecutive cancer patients (response rate 80.9%) in Austria, Italy and Spain. The Distress Thermometer (DT), the Mini-Mental Adjustment to Cancer (Mini-MAC), and the Patient Satisfaction with Doctor Questionnaire (PSQ) were used to assess psychosocial variables before chemotherapy. In the 5 days after chemotherapy, CINV was examined by using a daily diary, and the Functional Living Index for Emesis (FLIE) was used to assess QoL. Results: More than half of the patients reported nausea (54%), and a small percentage reported vomiting (14%). CINV had a negative impact on QoL (FLIE caseness, p < 0.01). Maladaptive coping (i.e. hopelessness-helplessness and anxious preoccupation) and emotional distress were associated with CINV (p < 0.05) and poorer QoL (p < 0.05). In logistic regression analysis, nausea was predicted by Mini-MAC/H (OR = 1.1, p = 0.03) and younger age (OR = 0.97, p = 0.04); negative impact on QoL was predicted by grade of chemotherapy emetogenesis (OR = 1.7, p < 0.01) and Mini-MAC/H (OR = 1.2, p = 0.04). Conclusions: Screening and assessment of psychological variables, especially coping, could help in identifying cancer patients at risk for chemotherapy-induced nausea, in spite of the use of antiemetic treatment.

Journal Section:
Editor's choice
Keywords:
Chemotherapy-induced nausea and vomiting, Coping, Hopelessness, Emotional distress
1.
Jordan K, Sippel C, Schmoll HJ: Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist 2007;12:1143-1150.
2.
Feyer P, Jordan K: Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol 2011;22:30-38.
3.
Jordan K, Gralla R, Jahn F, Molassiotis A: International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 2014;722:197-202.
4.
Hesketh PJ: Chemotherapy-induced nausea and vomiting. N Engl J Med 2008;358:2482-2494.
5.
Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJ, Gundy CM, Aaronson NK: Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer 2012;20:107-117.
6.
Molassiotis A, Stricker CT, Eaby B, Velders L, Coventry PA: Understanding the concept of chemotherapy-related nausea: the patient experience. Eur J Cancer Care (Engl) 2008;17:444-453.
7.
Liau CT, Chu NM, Liu HE, Deuson R, Lien J, Chen JS: Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs patients' reported outcomes. Support Care Cancer 2005;13:277-286.
8.
Ballatori E, Roila F, Ruggeri B, Betti M, Sarti S, Soru G, Cruciani G, Di Maio M, Andrea B, Deuson RR: The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer 2007;15:179-185.
9.
Fernández-Ortega P, Caloto MT, Chirveches E, Marquilles R, Francisco JS, Quesada A, Suárez C, Zorrilla I, Gómez J, Zabaleta P, Nocea G, Llombart-Cussac A: Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients' quality of life. Support Care Cancer 2012;20:3141-3148.
10.
Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J: Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006;24:4472-4478.
11.
Haiderali A, Menditto L, Good M, Teitelbaum A, Wegner J: Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US population. Support Care Cancer 2011;19:843-851.
12.
Farrell C, Brearley SG, Pilling M, Molassiotis A: The impact of chemotherapy-related nausea on patients' nutritional status, psychological distress and quality of life. Support Care Cancer 2013;21:59-66.
13.
Jacobsen PB, Andrykowski MA, Redd WH, Die-Trill M, Hakes TB, Kaufman RJ, Currie VE, Holland JC: Nonpharmacologic factors in the development of posttreatment nausea with adjuvant chemotherapy for breast cancer. Cancer 1988;61:379-385.
14.
Montgomery GH, Bovbjerg DH: Expectations of chemotherapy-related nausea: emotional and experiential predictors. Ann Behav Med 2003;25:48-54.
15.
Shih V, Wan HS, Chan A: Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide. Ann Pharmacother 2009;43:444-452.
16.
Higgins SC, Montgomery GH, Bovbjerg DH: Distress before chemotherapy predicts delayed but not acute nausea. Support Care Cancer 2007;15:171-177.
17.
Molassiotis A, Stamataki Z, Kontopantelis E: Development and preliminary validation of a risk prediction model for chemotherapy-related nausea and vomiting. Support Care Cancer 2013;21:2759-2767.
18.
Pirri C, Katris P, Trotter J, Bayliss E, Bennett R, Drummond P: Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study. Support Care Cancer 2011;19:1549-1563.
19.
Yap KY, Low XH, Chui WK, Chan A; Onco-Informatics Group: Computational prediction of state anxiety in Asian patients with cancer susceptible to chemotherapy-induced nausea and vomiting. J Clin Psychopharmacol 2012;32:207-217.
20.
Zook DJ, Yasko JM: Psychologic factors: their effect on nausea and vomiting experienced by clients receiving chemotherapy. Oncol Nurs Forum 1983;10:76-81.
21.
Watson M, Meyer L, Thomson A, Osofsky S: Psychological factors predicting nausea and vomiting in breast cancer patients on chemotherapy. Eur J Cancer 1998;34:831-837.
22.
Grassi L, Travado L, Gil F, Sabato S, Rossi E, Tomamichel M, Marmai L, Biancosino B, Nanni MG; SEPOS Group: Hopelessness and related variables among cancer patients in the Southern European Psycho-Oncology Study (SEPOS). Psychosomatics 2010;51:201-207.
23.
Price A, Goodwin L, Rayner L, Shaw E, Hansford P, Sykes N, Monroe B, Higginson I, Hotopf M, Lee W: Illness perceptions, adjustment to illness, and depression in a palliative care population. J Pain Symptom Manage 2012;43:819-832.
24.
Kim Y, Morrow GR: Changes in family relationships affect the development of chemotherapy-related nausea symptoms. Support Care Cancer 2003;11:171-177.
25.
Kim Y, Morrow GR: The effects of family support, anxiety, and post-treatment nausea on the development of anticipatory nausea: a latent growth model. J Pain Symptom Manage 2007;34:265-276.
26.
Efficace F, Baccarani M, Rosti G, Cottone F, Castagnetti F, Breccia M, Alimena G, Iurlo A, Rossi AR, Pardini S, Gherlinzoni F, Salvucci M, Tiribelli M, Vignetti M, Mandelli F: Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer 2012;107:904-909.
27.
Trevino KM, Fasciano K, Prigerson HG: Patient-oncologist alliance, psychosocial well-being, and treatment adherence among young adults with advanced cancer. J Clin Oncol 2013;31:1683-1689.
28.
Salsman JM, Grunberg SM, Beaumont JL, Rogers M, Paul D, Clayman ML, Cella D: Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives. J Natl Compr Canc Netw 2012;10:149-157.
29.
Molassiotis A, Aapro M, Dicato M, Gascon P, Novoa SA, Isambert N, Burke TA, Gu A, Roila F: Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage 2014;47:839-848.
30.
National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology. Guidelines for supportive care/distress management. Version 2. Jenkintown, NCCN, 2013. www.nccn.org.
31.
Donovan KA, Grassi L, McGinty HL, Jacobsen PB: Validation of the Distress Thermometer worldwide: state of the science. Psychooncology 2014;23:241-250.
32.
Grassi L, Johansen C, Annunziata MA, Capovilla E, Costantini A, Gritti P, Torta R, Bellani M; Italian Society of Psycho-Oncology Distress Thermometer Study Group: Screening for distress in cancer patients: a multicenter, nationwide study in Italy. Cancer 2013;119:1714-1721.
33.
Watson M, Law M, dos Santos M, Greer S, Baruch J, Bliss J: The Mini-MAC: further development of the Mental Adjustment to Cancer scale. J Psychosoc Oncol 1994;12:33-46.
34.
Grassi L, Buda P, Cavana L, Annunziata MA, Torta R, Varetto A: Styles of coping with cancer: the Italian version of the Mini-Mental Adjustment to Cancer (Mini-MAC) scale. Psychooncology 2005;14:115-124.
35.
Loblaw DA, Bezjak A, Bunston T: Development and testing of a visit-specific patient satisfaction questionnaire: the Princess Margaret Hospital Satisfaction with Doctor Questionnaire. J Clin Oncol 1999;17:1931-1938.
36.
Loblaw DA, Bezjak A, Singh PM, Gotowiec A, Joubert D, Mah K, Devins GM: Psychometric refinement of an outpatient, visit-specific satisfaction with doctor questionnaire. Psychooncology 2004;13:223-234.
37.
Lindley CM, Hirsch JD, O'Neill CV, Transau MC, Gilbert CS, Osterhaus JT: Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1992;1:331-340.
38.
Schipper H, Clinch J, McMurray A, Levitt M: Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol 1984;2:472-483.
39.
Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C: Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer 2003;11:522-527.
40.
Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro MS, Gandara D, Lindley CM: Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-109.
41.
Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D; ESMO/MASCC Guidelines Working Group: Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010;21(suppl 5):v232-v234.
42.
Grunberg SM, Warr D, Gralla RJ, Rapoport BL, Hesketh PJ, Jordan K, Espersen BT: Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - state of the art. Support Care Cancer 2011;19(suppl 1):S43-S47.
43.
Arpawong TE, Richeimer SH, Weinstein F, Elghamrawy A, Milam JE: Posttraumatic growth, quality of life, and treatment symptoms among cancer chemotherapy outpatients. Health Psychol 2013;32:397-408.
44.
Koller M, Heitmann K, Kussmann J, Lorenz W: Symptom reporting in cancer patients. II. Relations to social desirability, negative affect, and self-reported health behaviors. Cancer 1999;86:1609-1620.
45.
Badger TA, Braden CJ, Mishel MH: Depression burden, self-help interventions, and side effect experience in women receiving treatment for breast cancer. Oncol Nurs Forum 2001;28:567-574.
46.
Grassi L, Travado L, Moncayo Gil F, Sabato S, Rossi E; SEPOS Group: Psychosocial morbidity and its correlates in cancer patients of the Mediterranean area: findings from the Southern European Psycho-Oncology Study. J Affect Disord 2004;83:243-248.
47.
Wedding U, Koch A, Röhrig B, Pientka L, Sauer H, Höffken K, Maurer I: Depression and functional impairment independently contribute to decreased quality of life in cancer patients prior to chemotherapy. Acta Oncol 2008;47:56-62.
48.
Roscoe JA, Bushunow P, Morrow GR, Hickok JT, Kuebler PJ, Jacobs A, Banerjee TK: Patient expectation is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma. Cancer 2004;101:2701-2708.
49.
Roscoe JA, Morrow GR, Aapro MS, Molassiotis A, Olver I: Anticipatory nausea and vomiting. Support Care Cancer 2011;19:1533-1538.
50.
Akechi T, Okuyama T, Endo C, Sagawa R, Uchida M, Nakaguchi T, Sakamoto M, Komatsu H, Ueda R, Wada M, Furukawa TA: Anticipatory nausea among ambulatory cancer patients undergoing chemotherapy: prevalence, associated factors, and impact on quality of life. Cancer Sci 2010;101:2596-2600.
51.
Kamen C, Tejani MA, Chandwani K, Janelsins M, Peoples AR, Roscoe JA, Morrow GR: Anticipatory nausea and vomiting due to chemotherapy. Eur J Pharmacol 2014;722:172-179.
52.
Grassi L, Rosti G: Psychiatric and psychosocial concomitants of abnormal illness behaviour in patients with cancer. Psychother Psychosom 1996;65:246-252.
53.
Grassi L, Malacarne P, Maestri A, Ramelli E: Depression, psychosocial variables and occurrence of life events among patients with cancer. J Affect Dis 1997;44:21-30.
54.
Sirri L, Fava GA, Sonino N: The unifying concept of illness behavior. Psychother Psychosom 2013;82:74-81.
55.
Tecuta L, Tomba E, Grandi S, Fava GA: Demoralization: a systematic review on its clinical characterization. Psychol Med 2015;45:673-691.
56.
Pirri C, Bayliss E, Trotter J, Olver IN, Katris P, Drummond P, Bennett R: Nausea still the poor relation in antiemetic therapy? The impact on cancer patients' quality of life and psychological adjustment of nausea, vomiting and appetite loss, individually and concurrently as part of a symptom cluster. Support Care Cancer 2013;21:735-748.
© 2015 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.